文献速递肿瘤 PET/CT神经核医学

68Ga-DOTATATE与18F-FDG一体化PET/MRI在嗜铬细胞瘤和副神经节瘤中的初步研究

Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas: An Initial Study.
PubMed 文献 · Clin Nucl Med · 2022-01-01

该回顾性研究纳入11例患者共56个嗜铬细胞瘤和副神经节瘤(PPGL)病灶,比较68Ga-DOTATATE PET、18F-FDG PET、DWI-MRI及PET/MRI的病灶检出率;68Ga-DOTATATE PET检出率96.4%优于18F-FDG PET的85.7%和DWI-MRI的89.3%,PET/MRI联合DWI在转移性PPGL中可将检出率提高至100%,MRI对18F-FDG PET有附加价值但对68Ga-DOTATATE PET附加价值不大。

要点

  • 68Ga-DOTATATE PET病灶检出率96.4%(54/56),高于18F-FDG PET的85.7%(48/56)和DWI-MRI的89.3%(50/56)。
  • PET/MRI联合DWI在转移性PPGL中可将68Ga-DOTATATE和18F-FDG PET单独检出率提高至100%。
  • PPGL病灶在68Ga-DOTATATE PET的示踪剂摄取明显高于18F-FDG PET(原发灶P=0.009,转移灶P=0.033)。

核心结论

  • 68Ga-DOTATATE PET对PPGL的检出率高于18F-FDG PET。
  • 在一体化PET/MRI中,MRI对18F-FDG PET识别PPGL病灶有附加价值,但对68Ga-DOTATATE PET附加价值不大。

研究设计与样本

  • 回顾性纳入11例在2周内同时接受18F-FDG和68Ga-DOTATATE PET/MRI检查的患者,共分析56个PPGL病灶。
  • 计算并比较68Ga-DOTATATE PET、18F-FDG PET、DWI-MRI和PET/MRI的病灶检出率。

主要发现

  • 68Ga-DOTATATE PET病灶检出率为96.4%(54/56)(95%CI 87.7%-99.6%),高于18F-FDG PET的85.7%(48/56)(95%CI 76.3%-95.2%)和DWI-MRI的89.3%(50/56)(95%CI 80.9%-97.6%)。
  • PET/MRI联合DWI在转移性PPGL中可将68Ga-DOTATATE和18F-FDG PET单独检出率提高至100%。
  • PPGL病灶在68Ga-DOTATATE PET的示踪剂摄取明显高于18F-FDG PET(原发灶P=0.009,转移灶P=0.033)。

关键数值与推荐

  • 68Ga-DOTATATE PET病灶检出率96.4%(54/56)(95%CI 87.7%-99.6%)。
  • 18F-FDG PET病灶检出率85.7%(48/56)(95%CI 76.3%-95.2%)。
  • DWI-MRI病灶检出率89.3%(50/56)(95%CI 80.9%-97.6%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with metastatic potential. Both 68Ga-DOTATATE and 18F-FDG PET/CT scans have been demonstrated to have important roles in imaging PPGLs, but less is known about the performance of PET/MRI for PPGLs. The study is aimed to investigate whether diffusion-weighted imaging-MRI (DWI-MRI) has an added value to PET imaging in the identification of PPGL lesions by means of integrated PET/MRI. METHODS: Eleven patients who underwent both 18F-FDG and 68Ga-DOTATATE PET/MRI within 2 weeks were retrospectively included in the study. A total of 56 PPGL lesions were analyzed, and lesion-based detection rates of 68Ga-DOTATATE PET, 18F-FDG PET, DWI-MRI, and PET/MRI were calculated and compared, respectively. RESULTS: 68Ga-DOTATATE PET was superior to 18F-FDG PET and DWI-MRI in imaging PPGLs with a lesion-based detection rate of 96.4% (54/56) (95% confidence interval [CI], 87.7%-99.6%), 85.7% (48/56) (95% CI, 76.3%-95.2%), and 89.3% (50/56) (95% CI, 80.9%-97.6%), respectively. PET/MRI with DWI could improve the detection rate of 68Ga-DOTATATE and 18F-FDG PET alone up to 100% in metastatic PPGLs. Lesions of PPGL demonstrated markedly higher tracer uptake in 68Ga-DOTATATE PET than in 18F-FDG PET (P = 0.009 for primary lesion, P = 0.033 for metastases). CONCLUSIONS: 68Ga-DOTATATE PET showed a higher detection rate than 18F-FDG for PPGLs. In integrated PET/MRI, MRI had an added value to 18F-FDG PET but not much to 68Ga-DOTATATAE PET in identifying PPGL lesions.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Xu S, Pan Y, Zhou J, et al. Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas: An Initial Study. Clin Nucl Med. 2022. PMID: 35143455. doi:10.1097/RLU.0000000000004077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。